NEW YORK, NY / ACCESSWIRE / August 23, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Ardelyx, Inc. (NASDAQ:ARDX)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/ardelyx-inc-loss-submission-form?prid=18846&wire=1
Lead Plaintiff Deadline: September 28, 2021
Class Period: August 6, 2020 - July 19, 2021

Allegations against ARDX include that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.

Zymergen Inc. (NASDAQ:ZY)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/zymergen-inc-loss-submission-form?prid=18846&wire=1
Lead Plaintiff Deadline: October 4, 2021
This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.

Allegations against ZY include that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

View, Inc. f/k/a CF Finance Acquisition Corp. II (NASDAQ:VIEW)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/view-inc-f-k-a-cf-finance-acquisition-corp-ii-loss-submission-form?prid=18846&wire=1
Lead Plaintiff Deadline: October 18, 2021
Class Period: November 30, 2020 - August 16, 2021

Allegations against VIEW include that: (1) View had not properly accrued warranty costs related to its product; (2) there was a material weakness in View's internal controls over accounting and financial reporting related to warranty accrual; (3) as a result, the Company's financial results for prior periods were misstated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong